More Cycles of Intravenous Chemotherapy are Associated with Reduced Growth in Children with Retinoblastoma

作     者：Yu Qiong Yang Liang Yu Yin Xin Lin Bing Hao Xiao Yue Guan Hong Xia Xu Hong Feng Yuan Yu Qiong Yang;Liang Yu Yin;Xin Lin;Bing Hao;Xiao Yue Guan;Hong Xia Xu;Hong Feng Yuan

作者机构：Department of OphthalmologyDaping HospitalArmy Medical University(Third Military Medical University)Chongqing 400042China Department of Clinical NutritionDaping HospitalArmy Medical University(Third Military Medical University)Chongqing 400042China Institute of Hepatopancreatobiliary SurgerySouthwest HospitalArmy Medical University(Third Military Medical University)Chongqing 400038China 

出 版 物：《Journal of Nutritional Oncology》 (肿瘤营养学杂志（英文）)

年 卷 期：2021年第6卷第3期

页      面：126-133页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the Special Fund of Science and Technology Innovation for Social Livelihood in Chongqing(no.cstc2015shmszxl20107 Hongfeng Yuan). 

主　　题：Retinoblastoma Intravenous chemotherapy Height Survival 

摘      要：Background Chemotherapy can have a negative impact on the growth of children with different cancers.However,few studies have examined whether intravenous chemotherapy(IVC)affects the growth of children with retinoblastoma(RB).The present study evaluated the height differences(actual height compared to the age standardized value)and survival of pediatric RB patients treated with IVC.Methods This was an observational cohort study.A total of 87 pediatric RB patients were included.The study population was stratified into two groups based on the number of chemotherapy cycles administered(≤4 versus4).The height at baseline(before IVC),height after IVC and overall survival were compared between the two groups.Results Before IVC,no height differences were observed between the two groups(P=0.585).After IVC,all of the patients had a reduced height compared to the age standardized height(P=0.035).Patients who underwent more cycles of chemotherapy had a greater height difference compared to those who received fewer cycles(P=0.008).For those who had reduced height,the difference was positively associated with the number of chemotherapy cycles(r=0.279,P=0.043).Among the patients who exhibited a greater height difference,those who underwent more than four cycles of chemotherapy had a decreased overall survival(P=0.042).Conclusions Pediatric RB patients who underwent more cycles of chemotherapy were more likely to have a reduced height.Further studies are needed to determine the optimal treatment strategy to prevent the reduced growth while maintaining the benefits of chemotherapy.